Sai Parenterals Approves ₹101.86 Crore IPO Proceeds Shift Into Two Pharma Acquisitions

Q1 FY27 Consolidated Results YoY: Revenue at 178.7 Cr vs 33.4 Cr, up 435.1%. EBITDA at 27.3 Cr vs 5.9 Cr, up 360.6%. EBITDA Margin at 15.3% vs 17.7%, contraction of 250bps; other expenses grew 959% versus revenue growth of 435%. PAT at 7.9 Cr vs 1.4 Cr, up 459.9%. Noumed Pharmaceuticals Pty contributed revenue of 103.7 Cr but reported a loss of 9.0 Cr. Board proposed reallocating IPO proceeds toward acquiring 60% stakes in Saicriti Pharma for 83.8 Cr and Prathyak Laboratories for 15 Cr, replacing planned Unit I/II upgrades and a greenfield R&D centre, subject to shareholder approval.